Abstract
The versatility and potential of reductive cyclisation as a route to 5-membered N-heterocyclic structures of diverse complexity is demonstrated through selected examples.
Keywords: heterocycles, cycloaddition, leimgruber-batcho synthesis, reducing agents, cross-coupling reaction, cytotoxicity, human lung cancer
Current Organic Chemistry
Title: Reductive Cyclisation in the Synthesis of 5-Membered N-Heterocycles
Volume: 8 Issue: 16
Author(s): Petros G. Tsoungas and Andreas I. Diplas
Affiliation:
Keywords: heterocycles, cycloaddition, leimgruber-batcho synthesis, reducing agents, cross-coupling reaction, cytotoxicity, human lung cancer
Abstract: The versatility and potential of reductive cyclisation as a route to 5-membered N-heterocyclic structures of diverse complexity is demonstrated through selected examples.
Export Options
About this article
Cite this article as:
Tsoungas G. Petros and Diplas I. Andreas, Reductive Cyclisation in the Synthesis of 5-Membered N-Heterocycles, Current Organic Chemistry 2004; 8 (16) . https://dx.doi.org/10.2174/1385272043369755
DOI https://dx.doi.org/10.2174/1385272043369755 |
Print ISSN 1385-2728 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5348 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Multifunctional Nanomedicine Platform for Cancer Specific Delivery of siRNA by Superparamagnetic Iron Oxide Nanoparticles-Dendrimer Complexes
Current Drug Delivery Clinical Immunotherapy of B-Cell Malignancy Using CD19-Targeted CAR T-Cells
Current Gene Therapy Indoleamine 2,3-dioxygenase (IDO): Biology and Target in Cancer Immunotherapies
Current Cancer Drug Targets Increased Paternal Age and Child Health and Development
Current Pediatric Reviews Best Practices and Emerging Trends for Market Access to Personalised Medicine in the US and EU: Learnings for Global Developed and Emerging Markets
Current Pharmacogenomics and Personalized Medicine Preface
Recent Patents on Anti-Cancer Drug Discovery Theoretical Modelling of Potential Chk1 Inhibitors
Letters in Drug Design & Discovery Immobilization Techniques Applied to the Development of Biocatalysts for the Synthesis of Nucleoside Analogue Derivatives
Current Pharmaceutical Design The Recent Development of Farnesyltransferase Inhibitors as Anticancer and Antimalarial Agents
Mini-Reviews in Medicinal Chemistry Histone Deacetylase Inhibitors: A Review on Class-I Specific Inhibition
Mini-Reviews in Medicinal Chemistry <i>In Vitro</i> Anticancer Activity of Virgin Coconut Oil and its Fractions in Liver and Oral Cancer Cells
Anti-Cancer Agents in Medicinal Chemistry Silence of the Genes: A Targeted Approach to the Suppression of Specific Genes in Human Disease Using Small Interfering RNA (siRNA)
Current Genomics Advances on Semisynthesis, Total Synthesis, and Structure-Activity Relationships of Honokiol and Magnolol Derivatives
Mini-Reviews in Medicinal Chemistry A Recent Overview on Dermatological Applications of Liposomes
Recent Patents on Nanotechnology Anticancer Screening and Structure Activity Relationship Study of Some Semicarbazides and 1,2,4-Triazolin-5-ones
Letters in Drug Design & Discovery Molecular and Clinical Analysis of Predictive Biomarkers in Non-Small-Cell Lung Cancer
Current Medicinal Chemistry Anthracyclines Still Prove Effective in Anticancer Therapy
Mini-Reviews in Medicinal Chemistry Delivery Methods of Camptothecin and Its Hydrosoluble Analogue Irinotecan for Treatment of Colorectal Cancer
Current Drug Delivery Chemical Structure and Surface Modification of Dendritic Nanomaterials Tailored for Therapeutic and Diagnostic Applications
Current Topics in Medicinal Chemistry Role of Chemokines and Their Receptors in Cancer
Current Pharmaceutical Design